Revlimid (Lenalidomide) Patent Expiration, LOE Window & CMS Spending

Revlimid (Lenalidomide) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2027-04-27 (last listed 2028-03-08), 19 AB generics, $4.43B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN021880 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2027-04-27
Last Listed Patent or Exclusivity Date2028-03-08
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors19
2024 CMS Total Public Spend$4.43B
2024 Medicare Part D Spend$4.18B
2024 Medicaid Spend$254.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.